Evidence map›Paper›PMID 35190539›Full record

ArticleCell death discovery2022

Correction: Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance.

Yonggang Lu, Haoming Shen, Wenjie Huang, Sha He, Jianlin Chen, Di Zhang, Yongqi Shen, Yifan Sun

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yonggang Lu *Department of Hepatobiliary Surgery, Affiliated Liutie Central Hospital of Guangxi Medical University, Guangxi, China.
Haoming Shen *Department of Clinical Laboratory, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan, China.
Wenjie Huang *Department of Clinical Laboratory, Affiliated Liutie Central Hospital of Guangxi Medical University, Guangxi, China.
Sha HeDepartment of Hepatobiliary Surgery, Affiliated Liutie Central Hospital of Guangxi Medical University, Guangxi, China.
Jianlin ChenDepartment of Clinical Laboratory, Affiliated Liutie Central Hospital of Guangxi Medical University, Guangxi, China.
Di ZhangDepartment of Clinical Laboratory, The Third Xiangya Hospital of Central South University, Hunan, China.
Yongqi ShenDepartment of Oncology, Affiliated Liutie Central Hospital of Guangxi Medical University, Guangxi, China. gxnnsyq@163.com.ORCID http://orcid.org/0000-0002-1659-438X
Yifan SunDepartment of Clinical Laboratory, Affiliated Liutie Central Hospital of Guangxi Medical University, Guangxi, China. sunyifan@gxmu.edu.cn.ORCID http://orcid.org/0000-0003-3060-1539
Guangxi Medical University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35190539
PMCPMC8861155
OpenAlexW4212870245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.